RELATIONSHIP BETWEEN TACROLIMUS ORAL DOSE AND ADULT HEART ALLOGRAFT RECIPIENT GENOTYPE
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F20%3A00073381" target="_blank" >RIV/00159816:_____/20:00073381 - isvavai.cz</a>
Result on the web
<a href="https://www.ptfarm.pl/download/?file=File%2FActa_Poloniae%2F2020%2F5%2F777.pdf" target="_blank" >https://www.ptfarm.pl/download/?file=File%2FActa_Poloniae%2F2020%2F5%2F777.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.32383/appdr/127580" target="_blank" >10.32383/appdr/127580</a>
Alternative languages
Result language
angličtina
Original language name
RELATIONSHIP BETWEEN TACROLIMUS ORAL DOSE AND ADULT HEART ALLOGRAFT RECIPIENT GENOTYPE
Original language description
Determination patient genotype in selected ABCB, p450 CYP3A polymorphism and their potential phenotypic manifestation in measured tacrolimus level in relation oral dose. 35 adult patients after heart transplantation with itnmunosuppressant regimen containing oral tacrolimus, mycophenolate mofetil and corticosteroids were eligible. Patient weight, tacrolimus level and dose were collected retrospectively. DNA isolated from buccal smear was tested for presence of 1236C -> T (rs1128503), 2677G -> T/A (rs2032582), 3435C -> T (rs1045642) on ABCB gene, 1508C-4T (rs1057868) on POR gene, 522-191 C-sT (rs35599367) on CYP3A4 (CYP3A4*22) and 6986 A -> G (rs776746) on CYP3A5 (CYP3A5*3) gene. Statistical analysis was conducted by Chi-square test, statistical significance confirmed if p <0.05. Variant allele frequency in ABCB tested polymorphisms as follows: 0.53 (3435T), 0.4(1236T) and OA (2677TA). POR 1508T, CYP3A4*22 and CYP3A5*3 variant allele frequency was 0.27, 0.07 and 0 respectively. ABCB G2677T/A hcterozygotes (83%; n = 10) required tacrolimus oral dose above 0.075 mg/kg/day more often to reach level above 15 ng/mL in comparison to wild type homozygotes (p = 0.0263). Five patients out of six with tacrolimus level above 15 ng/mL with 2677GG genotype required tacrolimus dose below 0.075 mg/kg/day in comparison to variant allele carriers, who needed tacrolirnus dose above 0.075 mg/kg/day (p = 0.0464). Wild type ABCB haplotype patients (100%; n = 3) required dose below 0.075 mg/kg/day in contrast to one patient (12.5%) with heterozygote haplotype (p = 0.0474). Patients with wild type genotype 2677GG required lower oral tacrolimus dose than recommended in comparison to variant allele carriers, who needed higher dose to achieve such level 3 months after surgery.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ACTA POLONIAE PHARMACEUTICA
ISSN
0001-6837
e-ISSN
—
Volume of the periodical
77
Issue of the periodical within the volume
5
Country of publishing house
PL - POLAND
Number of pages
7
Pages from-to
777-783
UT code for WoS article
000597873300012
EID of the result in the Scopus database
—